P3 Health Partners Inc (PIII) Stock Forecast & Price Target
P3 Health Partners Inc · NASDAQ
$10.77+0.28 (+2.72%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering P3 Health Partners Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $14.00 to $14.00, so the covering firms are broadly aligned. The average target of $14.00 sits 30% above the current $10.77. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.77 next quarter toward $-3.00 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to P3 Health Partners Inc.
As of Jul, 1 of 2 firms rate PIII a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PIII EPS & revenue forecast
EPS · NEXT QUARTER
$-2.77
Range $-3.36 – $-2.17 · 2 analysts · -71% YoY
Next period, 2 analysts expect P3 Health Partners Inc to earn $-2.77 a share (range $-3.36 – $-2.17), versus $-9.67 a year earlier. Full-year consensus is $-8.45, growing to $-3.00 the year after.
REVENUE · NEXT QUARTER
$373.6M
Range $362.8M – $384.5M · 2 analysts · +8% YoY
Revenue is expected to reach $373.6M (range $362.8M – $384.5M), +8.2% year-over-year. Full-year consensus is $1.5B, rising to $1.6B next year.
Top analysts covering P3 Health Partners Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PIII.
#1
BH
Ben Haynor
Lake Street
Buy
$14.00+30.1% to target
Coverage
—
+ Follow
#2
Ryan Langston
TD Cowen
Hold
$14.00+30.1% to target
Coverage
—
+ Follow
#3
David Larsen
BTIG
Hold
No targeton PIII
Coverage
—
+ Follow
#4
BO
Brooks O'Neil
Lake Street
Buy
$20.00+85.8% to target
Coverage
—
+ Follow
#5
GT
Gary Taylor
TD Cowen
Hold
$0.25-97.7% to target
Coverage
—
+ Follow
PIII stock forecast FAQ
What is PIII's average 12-month price target?+
The 2 analysts with a live target average $14.00 for P3 Health Partners Inc over the next 12 months, ranging from a $14.00 high to a $14.00 low.
Is PIII stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PIII?+
2 analysts have an active rating on P3 Health Partners Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering PIII?+
Among analysts who currently cover PIII, Ben Haynor of Lake Street has the strongest overall Quantellect track record. Their current call is Buy with a $14.00 target.
What is P3 Health Partners Inc's projected EPS for next quarter?+
The consensus estimate is $-2.77 per share (range $-3.36 – $-2.17) across 2 analysts. Full-year EPS is projected at $-8.45, rising to $-3.00 the following year.
How much revenue is P3 Health Partners Inc expected to report next quarter?+
Consensus revenue is $373.6M (range $362.8M – $384.5M). Full-year revenue is projected at $1.5B, growing to $1.6B next year.
Have analysts been upgrading or downgrading PIII lately?+
As of Jul, 1 of 2 firms rate PIII a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PIII calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
